News & Press Releases: Archives

Slynd^® (drospirenone) is now covered by the Régie de l’assurance maladie du Québec

Duchesnay announces the launch of Vablys^® (dequalinium chloride vaginal tablets), an antiseptic and anti-infective treatment for bacterial vaginosis

Slynd^® (drospirenone), a new progestin-only contraceptive pill from Duchesnay which offers a 24-hour safe window for a missed pill

Postmenopausal Canadian women experiencing vaginal dryness and painful intercourse have a new oral once-daily prescription treatment, Osphena^® (ospemifene tablets) from Duchesnay

Population Council and Duchesnay Announce New International License Agreement for ANNOVERA^®

Proctofoam-HC^® Back in Canadian Pharmacies

Duchesnay Inc. is seeking Health Canada's approval for ospemifene for the treatment of moderate to severe dyspareunia and vaginal dryness, symptoms of vulvar and vaginal atrophy (VVA), a component of genitourinary syndrome of menopause (GSM)

Prevegyne^®, the ONLY 6-day vaginal tablet treatment for non-specific vaginitis/bacterial vaginosis, now with the convenience of a vaginal applicator

Duchesnay Donates $18,500 to Moisson Laurentides Food Bank

Mictoryl^® Pediatric (propiverine hydrochloride) now covered by several public drug plans to treat symptoms associated with overactive bladder

Mictoryl^® and Mictoryl^® Pediatric now available and distributed in Canada by Duchesnay

Duchesnay Expands its Women’s Health Product Portfolio with Acquisition of Osphena^® from Shionogi Inc.

Duchesnay Inc. is pleased to announce that Health Canada has granted market authorization for Mictoryl^®/Mictoryl^® Pediatric